Lycia Therapeutics files for IPO to fund antibody degrader platform

Lycia Therapeutics, a protein‑degradation startup built on research from Nobel laureate Carolyn Bertozzi, announced it has filed for an initial public offering.

The filing is intended to raise capital to advance its antibody degrader platform and support further development of its pipeline.

At the same time, two other biotech companies, TRexBio and Retension, are preparing their own Nasdaq listings and have set terms for their offerings.

These moves underscore growing investor interest in novel protein‑degradation technologies.